Bruker (BRKR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$58.50-1.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BRKR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 16.8% |
| Our one-year growth estimate | diamond | 4.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 12.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
BRKR — dividend update
Dated 2026-08-14
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on August 14, 2026, and is payable October 7, 2026, to shareholders of record at the close of business on September 21, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned here…
Why it matters: Thierry Bernard's experience may shape Bruker's plans and growth.
Watch forThe Board announced good plans that match Bernard's skills.
Also watch forNo big changes or plans were announced after Bernard was appointed.
Why it matters: Keeping EPS guidance shows confidence in making money and running the business well.
Supportive ifFY2026 non-GAAP EPS remains in the range of $2.10 to $2.15.
Worry ifFY2026 non-GAAP EPS guidance is lowered below $2.10.
Why it matters: A higher EPS means strong profits and backs management's growth story.
Supportive ifQ3 non-GAAP EPS reported above $0.49.
Worry ifQ3 non-GAAP EPS reported below $0.49.
Why it matters: A steady dividend shows financial health. It shows a commitment to giving value to shareholders.
Watch forBoard declares a quarterly cash dividend of $0.05 per share.
Also watch forBoard decides to suspend or reduce the dividend.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$204 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $444 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,985 loss on $10,000 · 39.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Strong bookings from new products can indicate market demand and growth potential.
Supportive ifBookings from new products rise a lot from one quarter to the next.
Worry ifBookings from new products show little to no growth quarter over quarter.
Why it matters: Keeping guidance shows that the business is stable and can grow.
Supportive ifManagement says FY2026 revenue guidance is still $3.54 to $3.57 billion.
Worry ifManagement lowers FY2026 revenue guidance from $3.54 to $3.57 billion.
Why it matters: Keeping guidance shows confidence in growth. This is true even with market issues.
Watch forManagement confirms FY26 revenue guidance of $3.54 to $3.57 billion.
Also watch forManagement cut the revenue forecast for FY26.
Why it matters: Strong growth in bookings shows demand for Bruker's products. This supports future sales.
Supportive ifBSI bookings growth reported at high-single digits year over year.
Worry ifBSI bookings growth reported below mid-single digits year over year.
Why it matters: This will show if Bruker can maintain its growth momentum after a weak Q1.
Supportive ifQ3 organic revenue growth is over 2%. This shows recovery and strong demand.
Worry ifQ3 organic revenue growth is under 1%. This shows ongoing challenges.
Why it matters: This would confirm Bruker's ability to achieve its EPS guidance for FY26.
Supportive ifQ3 non-GAAP EPS exceeds $0.55, supporting the full-year EPS guidance.
Worry ifQ3 non-GAAP EPS is below $0.50. This raises concerns about making money.
Why it matters: Better margins mean the company controls costs well. This shows they run operations efficiently.
Supportive ifNon-GAAP operating margin is over 14.5% in Q3. This shows strong cost control.
Worry ifNon-GAAP operating margin is under 12%. This suggests ongoing cost pressures.
Why it matters: Changes in academic demand will impact Bruker's growth in the research segment.
Watch forManagement says academic demand in the U.S. improved during Q3.
Also watch forManagement says U.S. academic demand remains weak in Q3.